Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
Clinical trial NCT02689141 · COMPLETED
Trial details
- NCT number
- NCT02689141
- Sponsor
- German CLL Study Group
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-04
- Primary completion
- 2017-07-13
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.